Cargando…

Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis

New oral drugs have considerably enriched the therapeutic armamentarium for the treatment of multiple sclerosis. This review focuses on the molecular pharmacodynamics of fingolimod, dimethyl fumarate (BG-12), laquinimod, and teriflunomide. We specifically comment on the action of these drugs at thre...

Descripción completa

Detalles Bibliográficos
Autores principales:	di Nuzzo, Luigi, Orlando, Rosamaria, Nasca, Carla, Nicoletti, Ferdinando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035221/ https://www.ncbi.nlm.nih.gov/pubmed/24876766 http://dx.doi.org/10.2147/DDDT.S52428

Ejemplares similares

Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint
por: Alborghetti, Marika, et al.
Publicado: (2022)

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies
por: Sehr, T., et al.
Publicado: (2016)

Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis
por: Massacesi, Luca, et al.
Publicado: (2022)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Multiple sclerosis - New treatment modalities
por: Totaro, Rocco, et al.
Publicado: (2015)

Promising Treatment for Multiple Sclerosis: Mitochondrial Transplantation
por: Picone, Pasquale, et al.
Publicado: (2022)

Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis
por: Rakers, Florian, et al.
Publicado: (2023)

Transcriptional upregulation of galectin-3 in multiple sclerosis
por: Mangano, Katia, et al.
Publicado: (2023)

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis
por: Aly, Lilian, et al.
Publicado: (2017)

Identification of CD4(+) T cell biomarkers for predicting the response of patients with relapsing-remitting multiple sclerosis to natalizumab treatment
por: Fagone, Paolo, et al.
Publicado: (2019)

The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
por: Eriksson, Irene, et al.
Publicado: (2018)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis
por: Singh, Manish, et al.
Publicado: (2011)

The Role of Macrophages in Neuroinflammatory and Neurodegenerative Pathways of Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis: Pathogenetic Cellular Effectors and Potential Therapeutic Targets
por: Mammana, Santa, et al.
Publicado: (2018)

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
por: Wei, Weipeng, et al.
Publicado: (2021)

Molecular Interventions towards Multiple Sclerosis Treatment
por: Metaxakis, Athanasios, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
por: Rodvold, Keith A, et al.
Publicado: (2019)

Antidepressant activity of fingolimod in mice
por: di Nuzzo, Luigi, et al.
Publicado: (2015)

Multiple Sclerosis: Impact on Oral Hygiene, Dysphagia, and Quality of Life
por: Covello, Francesco, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)

Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis
por: Luckey, Alison M, et al.
Publicado: (2015)

A concise synthesis of Fingolimod: an orally available drug for treating multiple sclerosis
por: Yan, Ning, et al.
Publicado: (2015)

Impaired Expression of Tetraspanin 32 (TSPAN32) in Memory T Cells of Patients with Multiple Sclerosis
por: Basile, Maria Sofia, et al.
Publicado: (2020)

Inflammation Subverts Hippocampal Synaptic Plasticity in Experimental Multiple Sclerosis
por: Nisticò, Robert, et al.
Publicado: (2013)

The use of immune modulating drugs for the treatment of multiple sclerosis
por: Al-Khamis, Fahd A.
Publicado: (2016)

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment
por: de Vries Schultink, A. H. M., et al.
Publicado: (2016)

Epigenetic Drugs for Multiple Sclerosis
por: Peedicayil, Jacob
Publicado: (2016)

In Vivo Non-radioactive Assessment of mGlu5 Receptor-Activated Polyphosphoinositide Hydrolysis in Response to Systemic Administration of a Positive Allosteric Modulator
por: Zuena, Anna R., et al.
Publicado: (2018)

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
por: Gibiansky, Ekaterina, et al.
Publicado: (2020)

Molecular Mimicry in Multiple Sclerosis
por: Libbey, Jane E., et al.
Publicado: (2007)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Molecular Research in Multiple Sclerosis
por: Fucito, Maurine, et al.
Publicado: (2022)

New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies
por: Moon, Sang Woong, et al.
Publicado: (2018)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia
por: Ahmed, Amir I. A., et al.
Publicado: (2015)

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
por: Paul, Friedemann, et al.
Publicado: (2008)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Plant-based production of an orally active cyclotide for the treatment of multiple sclerosis
por: Jackson, Mark A., et al.
Publicado: (2023)

Using an animal model to predict the effective human dose for oral multiple sclerosis drugs
por: Liu, Wei, et al.
Publicado: (2022)

Multiple Sclerosis and CCSVI: A Population-Based Case Control Study
por: Patti, Francesco, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_b62a328c5od1m96kbjanbbordt